The board (the "Board") of directors (the "Directors") of Sirnaomics Ltd. (the "Company", together with its subsidiaries, the "Group" or "Sirnaomics") hereby informed the shareholders and potential investors of the Company, that Dr. Francois Lebel, M.D., an experienced biopharmaceutical industry executive, has been appointed as Senior Vice President for preclinical and clinical development of the Group. Dr. Lebel is a strategic leader with broad drug development experience including immuno- oncology and nucleic acid therapeutics. Throughout his 30-year biopharma career at companies such as GSK, Pfizer, Baxter Healthcare, Medlmmune, and Chiron Corporation, Dr. Lebel has designed and managed international research and development programs to successfully achieve multiple product marketing approvals.

His recent senior leadership roles include Executive Vice President for Research & Development and Chief Medical Officer at Spectrum Pharmaceuticals (a Nasdaq listed company; stock code: SPPI), where he was responsible for preclinical and clinical development, regulatory affairs and pharmacovigilance/drug safety, and successfully secured a novel drug marketing authorization at the U.S. Food and Drug Administration (FDA) in 2022. After joining Sirnaomics as Senior Vice President for preclinical and clinical development, Dr. Lebel will take a leading role in the Group's late-stage product development of the innovative RNAi drug candidates.